Optimer Pharmaceuticals (OPTR +15%) says its board of directors has begun exploring a full range...
Wednesday, February 27, 10:31 AM ETOptimer Pharmaceuticals (OPTR +15%) says its board of directors has begun exploring a full range of strategic alternatives and has engaged JPMorgan and Centerview Partners as financial advisers. The board stated however, that there are no assurances that the review will result in any action and that there would be no further comment on the process until it's completed. The company also preannounced Q4 results of $0.02 per share, and appointed its chairman, Dr. Henry McKinnell, as CEO.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles